Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Cytostatic Therapy | Research

Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database

Authors: Duorui Nie, Jing Yang, Hao Zheng, Guihua Lai, Fei Wang, Jianxiong Cao, Chun Gong

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Objectives

This study aimed to compare the incidence, clinicopathological characteristics and survival results of pancreatic signet ring cell carcinoma (PSRCC) and pancreatic adenocarcinomas (PDAC), as well as to analyze the clinical characteristics related to the overall survival (OS) of PSRCC, and to establish an effective prognostic nomogram to predict the risks associated with patient outcomes.

Methods

A total of 85,288 eligible patients including 425 PSRCC and 84,863 PDAC cases were retrieved from the Surveillance, Epidemiology, and End Results database. The survival curve was calculated using the Kaplan–Meier method and differences in them were measured by Log-rank tests. The Cox proportional hazards regression model was used to identify independent predictors of OS in patients with PSRCC. A nomogram was constructed to predict 1-, 3-, and 5-year OS. The performance of the nomogram was measured by C-index, receiver operating characteristic (ROC) curve, decision curve analysis (DCA).

Results

The incidence of PSRCC is much lower than that of PDAC (10.798 V.S. 0.349 per millions). PSRCC is an independent predictor of pancreatic cancer with a poorer histological grade, a higher rate of lymph node and distant metastasis, and a poorer prognosis. We identified four independent prognostic factors including grade, American Joint Committee on Cancer Tumor-Node-Metastasis (TNM) stage, surgery and chemotherapy based on the Cox regression model. The C-index and DCA curves showed better performance of the nomogram than TNM stage. ROC curve analysis also showed that the nomogram had good discrimination, with an area under the curve of 0.840, 0.896, and 0.923 for 1-, 3-, and 5-year survival. The calibration curves showed good agreement between the prediction by the nomogram and actual observations.

Conclusion

PSRCC is a rare but fatal subtype of pancreatic cancer. The constructed nomogram in this study accurately predicted the prognosis of PSRCC, performed better than the TNM stage.
Literature
2.
go back to reference Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.CrossRefPubMed Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.CrossRefPubMed
3.
go back to reference Patel M, et al. The impact of epidemiological factors and treatment interventions on survival in patients with signet ring cell carcinoma of the pancreas. Am J Clin Oncol. 2018;41(12):1176–84.CrossRefPubMed Patel M, et al. The impact of epidemiological factors and treatment interventions on survival in patients with signet ring cell carcinoma of the pancreas. Am J Clin Oncol. 2018;41(12):1176–84.CrossRefPubMed
4.
go back to reference Jin D, et al. Signet-ring cell carcinoma as an independent prognostic factor for patients with urinary bladder cancer: a population-based study. Front Oncol. 2020;10:653.CrossRefPubMedPubMedCentral Jin D, et al. Signet-ring cell carcinoma as an independent prognostic factor for patients with urinary bladder cancer: a population-based study. Front Oncol. 2020;10:653.CrossRefPubMedPubMedCentral
5.
go back to reference Yendamuri S, et al. Prognostic implications of signet ring cell histology in esophageal adenocarcinoma. Cancer. 2013;119(17):3156–61.CrossRefPubMed Yendamuri S, et al. Prognostic implications of signet ring cell histology in esophageal adenocarcinoma. Cancer. 2013;119(17):3156–61.CrossRefPubMed
6.
go back to reference Zhou YW, et al. Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: a propensity score matching analysis based on the SEER database. Eur J Surg Oncol. 2021;47(8):2108–18.CrossRefPubMed Zhou YW, et al. Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: a propensity score matching analysis based on the SEER database. Eur J Surg Oncol. 2021;47(8):2108–18.CrossRefPubMed
7.
go back to reference Marcy M, et al. Signet ring cell carcinoma of the pancreas: a case report. Ann Pathol. 2002;22(4):314–6.PubMed Marcy M, et al. Signet ring cell carcinoma of the pancreas: a case report. Ann Pathol. 2002;22(4):314–6.PubMed
8.
go back to reference Naito Y, et al. A case of invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas producing a signet ring-type appearance on pancreatic duct brushing cytology. Cytopathology. 2009;20(6):406–8.CrossRefPubMed Naito Y, et al. A case of invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas producing a signet ring-type appearance on pancreatic duct brushing cytology. Cytopathology. 2009;20(6):406–8.CrossRefPubMed
9.
go back to reference Radojkovic M, Ilic D, Ilic I. Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review. Tumori. 2017;103(Suppl. 1):e50–2.CrossRefPubMed Radojkovic M, Ilic D, Ilic I. Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review. Tumori. 2017;103(Suppl. 1):e50–2.CrossRefPubMed
10.
go back to reference Terada T. Primary signet-ring cell carcinoma of the pancreas diagnosed by endoscopic retrograde pancreatic duct biopsy: a case report with an immunohistochemical study. Endoscopy. 2012;44(Suppl 2):E141–2.CrossRefPubMed Terada T. Primary signet-ring cell carcinoma of the pancreas diagnosed by endoscopic retrograde pancreatic duct biopsy: a case report with an immunohistochemical study. Endoscopy. 2012;44(Suppl 2):E141–2.CrossRefPubMed
11.
go back to reference Tracey KJ, et al. Signet ring carcinoma of the pancreas, a rare variant with very high CEA values. Immunohistologic comparison with adenocarcinoma. Dig Dis Sci. 1984;29(6):573–6.CrossRefPubMed Tracey KJ, et al. Signet ring carcinoma of the pancreas, a rare variant with very high CEA values. Immunohistologic comparison with adenocarcinoma. Dig Dis Sci. 1984;29(6):573–6.CrossRefPubMed
12.
go back to reference Chow LT, Chow WH. Signet-ring mucinous adenocarcinoma of the pancreas. Chin Med Sci J. 1994;9(3):176–8.PubMed Chow LT, Chow WH. Signet-ring mucinous adenocarcinoma of the pancreas. Chin Med Sci J. 1994;9(3):176–8.PubMed
13.
go back to reference McArthur CP, Fiorella R, Saran BM. Rare primary signet ring carcinoma of the pancreas. Mo Med. 1995;92(6):298–302.PubMed McArthur CP, Fiorella R, Saran BM. Rare primary signet ring carcinoma of the pancreas. Mo Med. 1995;92(6):298–302.PubMed
14.
go back to reference Keam B, et al. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011;137(9):1301–8.CrossRefPubMed Keam B, et al. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011;137(9):1301–8.CrossRefPubMed
15.
go back to reference Chen D, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram. Nat Commun. 2021;12(1):179.CrossRefPubMedPubMedCentral Chen D, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram. Nat Commun. 2021;12(1):179.CrossRefPubMedPubMedCentral
16.
17.
go back to reference He C, et al. Score for the overall survival probability of patients with pancreatic adenocarcinoma of the body and tail after surgery: a novel nomogram-based risk assessment. Front Oncol. 2020;10:590.CrossRefPubMedPubMedCentral He C, et al. Score for the overall survival probability of patients with pancreatic adenocarcinoma of the body and tail after surgery: a novel nomogram-based risk assessment. Front Oncol. 2020;10:590.CrossRefPubMedPubMedCentral
18.
go back to reference Steyerberg EW, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–38.CrossRefPubMedPubMedCentral Steyerberg EW, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–38.CrossRefPubMedPubMedCentral
20.
go back to reference Wu SG, et al. Survival in signet ring cell carcinoma varies based on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis. Expert Rev Gastroenterol Hepatol. 2018;12(2):209–14.CrossRefPubMed Wu SG, et al. Survival in signet ring cell carcinoma varies based on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis. Expert Rev Gastroenterol Hepatol. 2018;12(2):209–14.CrossRefPubMed
21.
go back to reference Li H, et al. Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program. J Gastrointest Oncol. 2019;10(5):979–88.CrossRefPubMedPubMedCentral Li H, et al. Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program. J Gastrointest Oncol. 2019;10(5):979–88.CrossRefPubMedPubMedCentral
22.
go back to reference Pernot S, et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428–38.CrossRefPubMedPubMedCentral Pernot S, et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428–38.CrossRefPubMedPubMedCentral
23.
24.
go back to reference Iasonos A, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRefPubMed Iasonos A, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRefPubMed
26.
go back to reference Li G, et al. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(10):3353–70.CrossRefPubMedPubMedCentral Li G, et al. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(10):3353–70.CrossRefPubMedPubMedCentral
28.
go back to reference Nie D, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral Nie D, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral
29.
go back to reference He C, et al. Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study. Cancer Manag Res. 2019;11:3981–91.CrossRefPubMedPubMedCentral He C, et al. Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study. Cancer Manag Res. 2019;11:3981–91.CrossRefPubMedPubMedCentral
30.
go back to reference Facciorusso A, et al. Echoendoscopic ethanol ablation of tumor combined with celiac plexus neurolysis in patients with pancreatic adenocarcinoma. J Gastroenterol Hepatol. 2017;32(2):439–45.CrossRefPubMed Facciorusso A, et al. Echoendoscopic ethanol ablation of tumor combined with celiac plexus neurolysis in patients with pancreatic adenocarcinoma. J Gastroenterol Hepatol. 2017;32(2):439–45.CrossRefPubMed
Metadata
Title
Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database
Authors
Duorui Nie
Jing Yang
Hao Zheng
Guihua Lai
Fei Wang
Jianxiong Cao
Chun Gong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02650-5

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.